#zepbound

#zepbound

Zepbound's new self-dosing option provides significant cost savings for patients willing to administer their own injections.

Zepbound gains FDA approval for treating obstructive sleep apnea, marking a breakthrough in weight-loss medication benefits.

Eli Lilly is significantly reducing the price of Zepbound to $399-$549 to combat counterfeits and enhance patient access.

Eli Lilly is suing telehealth companies for selling illegal copies of its drug Zepbound, which uses the active ingredient tirzepatide.

Eli Lilly launches Zepbound vials at lower prices to address supply shortages and boost access for patients.

Eli Lilly's new Zepbound vials improve drug access and affordability despite increased user difficulty compared to autoinjector pens.

Zepbound leads to more weight loss than Wegovy in clinical trials.

Eli Lilly's Zepbound missed sales estimates, raising concerns over the demand for popular weight loss drugs.

GLP-1 drugs Zepbound and Mounjaro significantly reduce diabetes risk by 94% while aiding substantial weight loss in pre-diabetic adults.

Jeanne's weight-loss journey with Zepbound transformed not only her health but also her 15-year marriage, requiring a renegotiation of their relationship.

Eli Lilly will sell weight loss drug Zepbound directly to consumers via LillyDirect, offering an affordable option for those without insurance.

Zepbound is the first ever FDA-approved medication for treating obstructive sleep apnea, particularly aimed at those with obesity.

Eli Lilly is introducing lower-cost single-use vials of Zepbound to meet demand and improve accessibility for weight-loss medications.

Eli Lilly has begun selling starter doses of Zepbound in vials online to boost supply and accessibility.

Eli Lilly's Zepbound pricing strategy has both improved access with lower starter dosages while raising concerns over transparency with existing drug prices.

Eli Lilly's medications are no longer in shortage, affecting the market for knockoff versions.

The FDA has resolved the shortage of Zepbound and Mounjaro, impacting compounded alternatives.